Physician profile
Megan E Deacon-Casey
NPI 1235112517
$25,552.36
in general payments reported to CMS, 2019-2025
12 companies · $8,221 in 2025
The $8,221 reported for 2025 was more than what 88% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,237 · 2020: $1,689 · 2021: $1,636 · 2022: $2,477 · 2023: $3,754 · 2024: $5,537 · 2025: $8,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,800 · Food and Beverage: $2,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $12,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,800.00 |
| Food and Beverage | $2,712.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $18,530.75 | 2019-2025 | Venacure 1470 Pro, Venacure 1470 Pro |
| Medtronic, INC. | $3,565.49 | 2021-2025 | Venaseal, Closurefast |
| Galderma Laboratories, L.P. | $989.32 | 2019-2025 | |
| Merz North America, INC. | $926.00 | 2019-2025 | Xeomin |
| Abbvie INC. | $782.46 | 2023-2025 | Botox |
| Bard Peripheral Vascular, INC. | $311.72 | 2021-2024 | Venclose Maven Catheter |
| Revance Therapeutics, INC. | $182.57 | 2024-2025 | Daxxify |
| Boston Scientific Corporation | $103.77 | 2022-2025 | Varithena Administration Pack |
| Venclose INC. | $64.82 | 2020 | |
| Allergan, INC. | $45.59 | 2020-2022 | |
| Cashflow Solutions, LLC | $30.92 | 2024-2025 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Team 1, LLC | $18.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Deacon-Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.